CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies

Core Viewpoint - CollPlant's rhCollagen BioInks align with the FDA's initiative to phase out animal testing for drug development, offering innovative alternatives for tissue regeneration and medical aesthetics [1][2][6] Group 1: FDA Announcement and Industry Impact - The FDA announced a plan on April 10, 2025, to phase out animal testing as a requirement for preclinical development of monoclonal antibodies and other drugs, aiming for a transition within 3-5 years [6][7] - This shift is intended to enhance drug safety, reduce development timelines, and promote ethical research practices [7] Group 2: CollPlant's Solutions - CollPlant's Collink.3D BioInks are designed for biofabrication of tissue-on-a-chip and organ-on-a-chip systems, which can replace traditional animal testing methods [1][2] - The BioInk products are compatible with in-vitro human-based systems, facilitating drug discovery and regenerative medicine applications [2] - CollPlant has developed Computational Modeling and Simulation (CM&S) methodologies to predict the behavior of regenerative implants, further reducing the need for animal studies [2] Group 3: Product Features and Applications - CollPlant's Collink.3D BioInk is the first and only line of human collagen BioInk products based on chemically modified plant-derived rhCollagen, produced with high purity and consistency [3][4] - The BioInk supports 3D bioprinting of tissues and organs, enabling real-time assessment of immune responses and tissue remodeling [4][5] - The product is characterized by optimal rheology at room temperature, high cell viability, biocompatibility, and non-immunogenic properties [5] Group 4: Company Overview - CollPlant focuses on regenerative and aesthetic medicine, utilizing 3D bioprinting technologies for tissue repair and organ manufacturing [8] - The company has a partnership with Allergan, an AbbVie company, for the development and commercialization of dermal and soft tissue fillers [9]